Organon & Co
NYSE:OGN
Intrinsic Value
Organon & Co. is a science based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars a... [ Read More ]
The intrinsic value of one OGN stock under the Base Case scenario is 56.17 USD. Compared to the current market price of 18 USD, Organon & Co is Undervalued by 68%.
Valuation Backtest
Organon & Co
Run backtest to discover the historical profit from buying and selling OGN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Organon & Co
Current Assets | 4.5B |
Cash & Short-Term Investments | 693m |
Receivables | 1.7B |
Other Current Assets | 2.1B |
Non-Current Assets | 7.6B |
PP&E | 1.4B |
Intangibles | 5.1B |
Other Non-Current Assets | 1.1B |
Current Liabilities | 2.9B |
Accounts Payable | 1.3B |
Accrued Liabilities | 1.4B |
Other Current Liabilities | 215m |
Non-Current Liabilities | 9.2B |
Long-Term Debt | 8.8B |
Other Non-Current Liabilities | 459m |
Earnings Waterfall
Organon & Co
Revenue
|
6.3B
USD
|
Cost of Revenue
|
-2.5B
USD
|
Gross Profit
|
3.7B
USD
|
Operating Expenses
|
-2.4B
USD
|
Operating Income
|
1.3B
USD
|
Other Expenses
|
-289m
USD
|
Net Income
|
1B
USD
|
Free Cash Flow Analysis
Organon & Co
What is Free Cash Flow?
OGN Profitability Score
Profitability Due Diligence
Organon & Co's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Organon & Co's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
OGN Solvency Score
Solvency Due Diligence
Organon & Co's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Score
Organon & Co's solvency score is 38/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OGN Price Targets Summary
Organon & Co
According to Wall Street analysts, the average 1-year price target for OGN is 21.93 USD with a low forecast of 15.15 USD and a high forecast of 29.4 USD.
Ownership
OGN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
OGN Price
Organon & Co
Average Annual Return | -5.62% |
Standard Deviation of Annual Returns | 1.32% |
Max Drawdown | -71% |
Market Capitalization | 4.6B USD |
Shares Outstanding | 256 590 000 |
Percentage of Shares Shorted | 4.88% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Organon & Co. is a science based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company is headquartered in Jersey City, New Jersey and currently employs 9,300 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in developing and delivering health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. Organon has a portfolio of contraception and fertility brands, such as Nexplanon or Implanon NXT, which is a patented long-acting reversible contraceptive. The Company’s Biosimilars portfolio spans across immunology and oncology treatments. The company also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. The firm sells these products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. The company operates approximately six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.
Contact
IPO
Employees
Officers
The intrinsic value of one OGN stock under the Base Case scenario is 56.17 USD.
Compared to the current market price of 18 USD, Organon & Co is Undervalued by 68%.